NCT00445094View on ClinicalTrials.gov

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

PHASE4CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

InfectionPneumonia

Interventions

DRUG

MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

DRUG

Comparator: amikacin / Duration of Treatment: 3 Days

DRUG

Comparator: tazocin / Duration of Treatment: 3 Days

DRUG

Comparator: vancomycin / Duration of Treatment: 3 Days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00445094 - A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092) | Biotech Hunter | Biotech Hunter